NCT05837806View on ClinicalTrials.gov

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Neoadjuvant Immunotherapy
Interventions
DRUG

tislelizumab+disitamab-vedotin

Patients enrolled will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin (RC48) 2.0mg/kg intravenously.

Trial Locations (1)

Unknown

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Second Hospital

OTHER